TABLE 2.

Key parameters for modeling low-threshold buprenorphine treatment on-site at syringe service programs (SSPs) versus standard of care buprenorphine treatment within RESPOND

Processes	Standard of care buprenorphine treatment	Low-threshold SSP buprenorphine	Source
Patient population	21% report recent injection drug use	76% report recent injection drug use	MA DPH
Percentage actively using following initiation	26%	90%	CTN-051, Hood et al. [19]
Percentage actively using while receiving treatment	28%	34%	Calibrated, informed by CTN-051, CTN-027, Hood et al. [19], Bachhuber et al. [18]
Weekly probability of discontinuing treatment	3% (17.6% retained at 1 year)	1.3% (51% retained at year)	Morgan et al. [4], Bachhuber et al. [18], Stancliff et al. [20]
Overdose hazard reduction while on treatment	0.4	0.4	Sordo et al. [26]
Percentage experiencing overdose per year while on treatment	0.10%	0.28%	Model output resulting from input parameters
Costs
Health-care utilization (i.e. clinical visits)	$65.24/week	$46.03/week	Expert opinion (physicians prescribing buprenorphine in various settings, including an SSP)
Pharmaceutical costs (i.e. buprenorphine)	$48.71/week	$48.71/week	Federal Supply Schedule 2020

MA DPH = Massachusetts Department of Public Health; CTN = Clinical Trials Network